Cabometyx (cabozantinib) — Highmark

Initial criteria

• age ≥ 12 years
• diagnosis of locally advanced or metastatic differentiated thyroid cancer (ICD-10: C73)
• disease progression following prior VEGFR-targeted therapy
• radioactive iodine-refractory OR ineligible for radioactive iodine therapy